Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.40 |
| ▸ | CDK2 | P24941 | 4/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.39 |
| ▸ | TCF7L2 | Q9NQB0 | 3/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107639 | 0.98 | HDAC1 (0.45) | HDAC1CCNA2CDK2CCNA1CHEK1 | |
| SCHEMBL3092925 | 0.96 | HDAC1 (0.45) | HDAC1CCNA2CDK2CCNA1CHEK1 | |
| SCHEMBL741142 | 0.86 | ABL1 (0.53) | HDAC1CCNA2CDK2CCNA1CTNNB1 | |
| SCHEMBL4632620 | 0.85 | HDAC1 (0.43) | HDAC1CCNA2CDK2CCNA1CHEK1 | |
| SCHEMBL741580 | 0.84 | ABL1 (0.53) | HDAC1CCNA2CDK2CCNA1CTNNB1 | |
| SCHEMBL3090077 | 0.83 | PRKD1 (0.39) | HDAC1CTNNB1TCF7L2AURKAPRKD1 | |
| SCHEMBL739415 | 0.82 | ABL1 (0.53) | HDAC1CTNNB1TCF7L2AURKAPRKD1 | |
| SCHEMBL4633592 | 0.81 | HDAC6 (0.40) | HDAC1AURKA | |
| SCHEMBL3102304 | 0.81 | FLT3 (0.50) | HDAC1CDK2CTNNB1TCF7L2AURKA | |
| SCHEMBL3104562 | 0.80 | ABL1 (0.52) | HDAC1AURKAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803829-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-28 | — | — | US | claimed |
| US-20100022532-A1 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | US | claimed |
| EP-2007380-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-31 | — | — | EP | claimed |
| EP-1711177-B1 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-05-28 | — | — | EP | claimed |
| WO-2007113198-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-11 | — | — | WO | claimed |
| EP-1711177-A1 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS | Pfizer Italia S.r.l. (IT) | 2006-10-18 | — | — | EP | claimed |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-25 | — | — | US | claimed |
| WO-2005074922-A1 | 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | PFIZER ITALIA S.R.L. (IT) | 2005-08-18 | — | — | WO | claimed |
| US-8481584-B2 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-07-09 | — | — | US | disclosed |
| US-20120165311-A1 | 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-28 | — | — | US | disclosed |
| US-7803829-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-28 | — | — | US | disclosed |
| US-20100022532-A1 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | US | disclosed |
| EP-2007380-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-31 | — | — | EP | disclosed |
| EP-1711177-B1 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007113198-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-11 | — | — | WO | disclosed |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022532-A1 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | ABL1, ABL2, LTK | HDAC1 3934/4885CCNA2 3055/4885CDK2 433/4885 |
| US-20120165311-A1 | 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K3 | HDAC1 801/4885CCNA2 923/4885CDK2 46/4885 |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | MAP3K19, MAP3K1, MAP3K3 | HDAC1 786/4885CCNA2 912/4885CDK2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.